ArticleVaccine2025
Recombinant zoster vaccine and the risk of dementia.
Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Effectiveness of the Recombinant Zoster Vaccine Against Herpes Zoster, Herpes Zoster Ophthalmicus, Postherpetic Neuralgia and Dementia: A Systematic Review and Meta-Analysis.Reviews in medical virology · 2026Pooled it
- Predictors of initiation and completion of Shingrix vaccination in immunocompetent adults newly eligible for vaccination from 2018-2024.Human vaccines & immunotherapeutics · 2026Article
- Immunofitness in the elderly: The role of vaccination in promoting healthy aging.Human vaccines & immunotherapeutics · 2026Review
- Association Between Herpes Zoster Vaccination and Dementia Risk: A Systematic Review and Meta-Analysis.Vaccines · 2026Review
- Varicella zoster virus and the central nervous system.Nature reviews. Microbiology · 2026Review
- Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Impact of Vaccines Across the Lifespan: A New Perspective in Public Health-Conclusions of an Expert Panel-Part 1.Vaccines · 2026Review
- Recombinant zoster vaccine is associated with a reduced risk of dementia.Nature communications · 2026Article
- Association between shingles vaccination and slower biological aging: evidence from a US population-based cohort study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Herpes zoster vaccination and incident dementia in Canada: an analysis of natural experiments.The Lancet. Neurology · 2026Article
- Beyond the Virological Benefits of the Herpes Zoster Vaccine in the Context of Primary Care.Vaccines · 2026Article
- Infection, vaccination and risk of dementia: a proposed immunological model.Frontiers in immunology · 2026Review
- A high-throughput, quantitative platform using 2D dissociated human cerebral organoids to model neuroinflammation in Alzheimer's disease.NPJ dementia · 2026Article
- Article
- Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections.NPJ vaccines · 2025Article
- Article
- Article
- Review
- Strategic latency with temporal mutualism: a coevolutionary model of the host-varicella-zoster virus relationship.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHerpes zoster is a potential risk factor for dementia. The effectiveness of the recombinant zoster vaccine for preventing dementia is uncertain.
methodsThis retrospective cohort study used de-identified claims data from the Optum Labs Data Warehouse database from January 1, 2017, to December 31, 2022, to determine whether the recombinant zoster vaccine is associated with a reduced risk of dementia. Immunocompetent patients with ≥365 days of continuous enrollment were included, with the risk period starting upon age-eligibility for the recombinant zoster vaccination. Cox regression adjusted for time-fixed and time-updated measures every six months was implemented to estimate hazard ratios for dementia. Herpes zoster diagnosis and antiviral therapy were also assessed.
resultsThere were 4,502,678 individuals (median [IQR] age, 62 [54-71] years; 51 % female) included in this study: 206,297 (4.6 %) were partially vaccinated, and 460,413 (10.2 %) were fully vaccinated. The incidence rate of dementia was 99.1 cases per 10,000 person-years in the fully vaccinated group, 108.2 cases per 10,000 person-years in the partially vaccinated group, and 135.0 cases per 10,000 person-years in the unvaccinated group. After adjustment, vaccination was significantly associated with a decreased risk of dementia for two doses (hazard ratio (HR): 0.68; 95 % CI: 0.67-0.70; P < .001) and for one dose (HR 0.89; 95 % CI: 0.87-0.92; P < .001). Having a herpes zoster diagnosis before the first vaccination dose was associated with an increased hazard of dementia (HR 1.47; 95 % CI: 1.42-1.52; P < .001) compared to those with no diagnosis. Antivirals used to treat zoster infection were protective against dementia (HR 0.42; 95 % CI: 0.40-0.44; P < .001).
conclusionsThese findings suggest that the recombinant zoster vaccine is associated with a decreased risk of dementia and highlight an additional benefit of vaccination beyond preventing herpes zoster.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.